Tony Huge

Tesamorelin Exposed: Same Growth Hormone, Different Doorway: Tony Huge’s Video Guide

Table of Contents

Tesamorelin does one thing: it raises your own growth hormone. Everything it does to visceral fat, it does through that hormone, and the FDA label says so. Tony Huge’s argument in this video is that if growth hormone is the whole mechanism, then the molecule that released it is interchangeable, and the tesamorelin vs ipamorelin comparison is his worked example: a peptide costing a tenth as much that also releases growth hormone in pulses deserves the same credit. He walks the label, the fat-cell biology, the pivotal trial, the strongest counterargument, and the money, and then says plainly where sound reasoning stops being a trial.

Video: The Peptide Pandemic is Destroying Lives | Tesamorelin Exposed. Published July 30, 2026. Watch on YouTube.

What the video covers

A delivery system for your own growth hormone

Tony’s opening claim is the entire argument. Tesamorelin has no fat-burning mechanism of its own. It is a stabilized analog of the growth hormone releasing hormone your hypothalamus already makes. It binds GHRH receptors on the somatotrophs in the pituitary, raises cAMP and PKA signaling, and triggers a pulse of your own growth hormone, which then stops. It is not growth hormone itself, and it does not go into fat cells.

He reads the approved label to make the point: it acts on pituitary somatotroph cells to stimulate synthesis and pulsatile release of endogenous growth hormone, which is anabolic and lipolytic, and growth hormone exerts its effects by interacting with receptors on target cells including adipocytes. What the label does not say matters as much. No direct adipocyte action, no peripheral pathway, no mechanism bypassing the pituitary. The label attributes the fat effect to growth hormone acting on its receptors. If growth hormone is the whole mechanism, Tony argues, the molecule that raised it is interchangeable.

What growth hormone does when it reaches the fat cell

The cascade is the same regardless of what released the hormone, and Tony walks it once. Growth hormone binds its receptor on the fat cell surface, JAK2 and STAT5 signaling fire inside the cell, lipoprotein lipase falls so less circulating fat is pulled into the depot, the storage brakes G0S2 and FSP27 are suppressed, triglycerides are hydrolyzed to fatty acids, and the fat gets oxidized rather than restored. He corrects a common claim on the way: people say growth hormone makes more of the fat-burning enzymes HSL and ATGL, but when researchers check human fat tissue they do not see more of them. Growth hormone works by turning off the brakes, which come mostly from insulin. Same result, different method.

Visceral fat responds first because it is not ordinary fat. It has higher blood flow, drains into the portal vein, shows higher stimulated lipolysis, and carries an adrenoceptor ratio that favors release. Subcutaneous fat has less blood flow, drains systemically, and its receptor ratio favors storage. That is why the pivotal trial data Tony cites shows a visceral fat reduction of roughly 15.4% against placebo, and an 18% figure at the longer time point, mostly in HIV patients where growth hormone research tends to happen. His reading of that trial is not that tesamorelin causes visceral fat loss but that growth hormone does, with tesamorelin as the doorway.

Same hormone, different doorway

Ipamorelin raises growth hormone through the ghrelin receptor rather than the GHRH receptor. Different doorway into the pituitary, identical hormone arriving at the fat cell, and still pulsatile with a short half-life. Tony’s four-step case: tesamorelin’s only mechanism is raising growth hormone; growth hormone acting on fat cells is what reduces visceral fat; what matters is that growth hormone reaches the fat in a pulsatile pattern; ipamorelin raises it in the same pulsatile pattern. He is explicit that the missing piece is a trial. There is no study showing ipamorelin reduces visceral fat. His counter is a question: is there any reason growth hormone released through a different receptor would behave differently? Something about GHRH-driven growth hormone would have to be special, and nobody has shown that.

“The mechanism argument is sound. The outcome has never been measured in a human. Sound reasoning is not a trial.”

Tony Huge, 25:20

The MK-677 objection and the cortisol answer

The strongest case against him comes from a two-year study in the Annals of Internal Medicine on an oral ghrelin mimetic, MK-677, in older adults. It significantly increased fat-free mass and produced no significant change in abdominal visceral fat or total fat. A ghrelin-receptor drug raised growth hormone and visceral fat did not move. Tony’s answer has two parts.

First, the same study reported increased cortisol, and cortisol drives visceral fat storage. Cushing’s syndrome is his proof: chronic cortisol excess produces central and visceral obesity while sparing limb fat. Growth hormone and cortisol pull in opposite directions on that depot, and he hypothesizes that the cortisol rise negated the fat effect. Second, and in his view the better explanation, is pattern. Pulsatile growth hormone burns more fat; continuous growth hormone builds more muscle. MK-677 is long-acting and holds growth hormone elevated for up to 24 hours, which is why bodybuilders use it in place of injected growth hormone and why it builds so much muscle. Ipamorelin uses the same receptor but clears quickly and produces a spike that returns to baseline, so its response curve looks like tesamorelin’s rather than MK-677’s. On his comparison table, tesamorelin does not raise cortisol, MK-677 and GHRP-2 and GHRP-6 do, and ipamorelin does not, though only in swine data.

The money

Compounded tesamorelin runs around $350 a month by Tony’s figures, brand name far higher, against roughly $40 for ipamorelin, a gap of 10 to 100 times that manufacturing cost cannot explain. His analysis as a lawyer is that the gap is marketing, research recovery, and patent defense, reinvested into presenting the clinical evidence in a way that makes one molecule look magic. The undisputed facts he lists: patents covering further indications run to 2040, approval came through an orphan designation granting market exclusivity, and insurance covers it essentially only with an HIV lipodystrophy diagnosis.

Cheat Sheet Pivot

What Tony reported and what the cited research showed, not instructions.

  • The tesamorelin trials showed roughly 15.4% visceral fat reduction against placebo and about 18% at the longer time point, in a largely HIV-positive population.
  • Ipamorelin has never been tested for visceral fat in humans; its cortisol neutrality comes from swine data, and its only completed human RCT was in a different indication.
  • Tony says he would never have a client run ipamorelin by itself for fat loss. He stacks it, and he treats lowering cortisol as part of any fat-loss stack regardless of which secretagogue is involved.
  • User reports on ipamorelin cluster around sleep quality, recovery, strength, and less hunger than GHRP-6, and almost never isolate fat loss, let alone visceral fat, which needs a scan rather than a mirror.
  • Reported side effects exist for all of these compounds; Tony’s position is that quality sourcing, stacking to mitigate, and starting at the minimum effective dose is how he avoids them.

The growth hormone secretagogues Tony compares here are all in the Miracle Molecules Cheat Sheet. For his earlier, more favorable write-up of the compound itself, read Tesamorelin: The FDA-Approved GHRH That Reduces Visceral Fat, and for the stack he has actually run for years, see CJC-1295 + Ipamorelin: The GH Peptide Stack I’ve Run for 4 Years.

Where the evidence stops

Tony gives the tesamorelin side its full hearing. It has human trials, FDA approval, and long-term safety data. Ipamorelin has none of those. The defenders’ position, that there are no studies, is correct. His position is that the mechanism is sound and common sense fills the gap until a trial is run, and he says in the same breath that sound reasoning is not a trial. The cortisol explanation for the MK-677 result is a hypothesis. The pulsatile-versus-continuous explanation is a hypothesis. Nobody has scanned visceral fat in people on ipamorelin.

What he is confident about is the label. Tesamorelin’s fat effect runs through growth hormone, with no second pathway documented anywhere, and any argument that it is special has to explain what GHRH-driven growth hormone does that other growth hormone does not.

Keep going

For the continuous-release end of the comparison with bloodwork attached, read MK-677 (Ibutamoren) Honest Review: 12 Weeks, Full Bloodwork. New companion articles reach the tonyhuge.is email list first, and the peptide archive is on tonyhuge.is.

Popular Category